<img src="https://ml.globenewswire.com/Resource/Download/d0c282b6-d496-45a8-a941-33fa5c3e824c?size=2" nborder="0" align="left" hspace="5" vspace="5" title="BCC Logo 1200-630.png" alt="BCC Research LLC"/>“The market is projected to expand from $70.8 billion in 2024 to $125.5 billion by 2030 as precision medicine, CAR-T therapies, bispecific antibodies and targeted treatments reshape hematologic cancer care.”Boston, Aug. 26, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The global blood cancer therapeutics market is projected to grow from $70.8 billion in 2024 to $125.5 billion by 2030, at a compound annual growth rate (CAGR) of 10.2% during 2025–2030, according to <a href="https://www.globenewswire.com/Tracker?data=dOiFm8pgT9hHvHXr1Omn8bz_4tlYO6IvE7DAImRXaNLyvnp9q4fFNWlT0r2Zt0cMOdrNSujqXcoTBswGck8ZgIzmnI4nLq1nOA8hcqxt3fZnLCkvlp9fMlTdXJ5ysEj69KnhTKi69zd-VJPxkB04zXnAAbbliuT0ysfJ9f9kg70AKqjspFZe_xLApo1QmmJ9OFn9Mq8aS7DxfzP1csPauxLEkjT1N4qlW3pKYqjXo19OS_BH9uRpVt3iXomXI2hfXafS6Vwie76FqFZjvBfu3ETKH-YRqQcuoN2SZRFmaPVo5QE4_cX6j8JI-3nMas5CCyBE5HZ-9Gko89M-kezK3g==" rel="nofollow" target="_blank" title="Blood Cancer Therapeutics: Global Markets to 2030">Blood Cancer Therapeutics: Global Markets to 2030</a>, a new          report published by BCC Research. The report identifies precision medicine adoption, accelerating R&amp;D investment, and a robust pipeline of novel therapies as the primary forces reshaping this high-growth oncology segment. Key Findings • The global blood cancer therapeutics market is valued at $70.8 billion in 2024 and is forecast to reach $125.5 billion by 2030 (CAGR of 10.2%, 2025–2030), underpinned by rising global blood cancer incidence linked to lifestyle risk factors including obesity, poor diet, and smoking, and sustained by expanding treatment pipelines across multiple hematologic indications. • North America dominates the market, accounting for 52.4% of global revenue, supported by favorable reimbursement conditions, a well-established oncology infrastructure, and rapid adoption of novel therapeutics including CAR T-cell therapies and bispecific antibodies. • R&amp;D investment is a critical structural driver: the top 50 pharmaceutical companies increased R&amp;D spending by nearly 60% between 2012 and 2022, reaching approximately $167 billion in 2022 — fueling a robust pipeline of targeted therapies and immunotherapies with multiple new regulatory approvals across geographies. • Precision medicine is transforming treatment paradigms, with genetic and molecular profiling enabling increasingly individualized therapeutic regimens. Government programs — including the U.S. National Cancer Institute and Australia's Medical Research Future Fund — continue to underwrite foundational research that accelerates clinical translation. • Emerging modalities are redefining the therapeutic landscape: CAR T-cell therapies (including Breyanzi and Abecma), bispecific T-cell engager (BiTE) antibody technologies such as BLINCYTO, antibody-drug conjugates (ADCs) including Trodelvy, POLIVY, and ADCETRIS, second-generation BTK inhibitors (Calquence), and first-in-class protein degraders targeting AML are broadening treatment options and extending addressable patient populations. • The competitive landscape features a diverse mix of global pharmaceutical leaders and specialty players, including AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GSK plc, Johnson &amp; Johnson Innovative Medicine, Lilly USA LLC, Merck &amp; Co. Inc., Novartis AG, Sanofi, Pfizer Inc., Jazz Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Knight Therapeutics Inc., Oncopeptides, and Shanghai Henlius Biotech Inc. Market Drivers The blood cancer therapeutics market is operating at the intersection of several powerful structural forces. Escalating global cancer incidence — driven by aging populations and modifiable risk factors — is generating sustained demand for more effective and personalized treatment options. Simultaneously, the convergence of genomic medicine and immunotherapy is producing a generation of therapies that outperform earlier standards of care on efficacy and tolerability. Regulatory acceleration in Europe and other jurisdictions is shortening time-to-market for innovative therapies, while expanding healthcare infrastructure across Asia-Pacific — particularly in China, India, and Japan — is opening substantial new patient populations to modern therapeutics. Underpinning this growth is a reinforcing cycle of capital allocation: higher R&amp;D investment is generating more approvals, which in turn attract additional investment. The pipeline extends beyond current approvals into subcutaneous formulations improving patient convenience, novel delivery platforms such as mesoporous silica nanoparticle-supported lipid bilayers for targeted leukemia cell delivery, and predictive platforms like the Cancer Immunotherapy Response Research Platform (CIRRP) designed to identify patients most likely to benefit from immunotherapy — meaningfully improving treatment efficiency and outcomes. Investment Considerations For investors, blood cancer therapeutics represents one of the most compelling long-cycle growth opportunities within the global oncology sector, supported by durable demand fundamentals and an exceptionally active innovation pipeline. Companies with diversified hematology portfolios — spanning targeted therapies, immunotherapies, and next-generation modalities such as ADCs and protein degraders — are best positioned to capture disproportionate revenue as older therapies face biosimilar erosion. Biosimilars saved an estimated $12.4 billion in 2023 alone, with 63 FDA-approved biosimilars on the market by end of 2024, creating material pricing headwinds for legacy products. Additional risk factors include HTA reimbursement complexity in Europe, regulatory scrutiny of accelerated approval pathways, and persistent access gaps in GCC and developing markets. Investors should prioritize exposure to companies with late-stage differentiated assets, global commercial infrastructure, and strategic positioning in precision oncology. About the Report <a href="https://www.globenewswire.com/Tracker?data=dOiFm8pgT9hHvHXr1Omn8bz_4tlYO6IvE7DAImRXaNLyvnp9q4fFNWlT0r2Zt0cM-g2tVCVTe7ZcKfiT7pfk85vR-qZAWl23Bzlr1Dq7xSfSa9EVssQNbVfCAHl4RM77JUN8ao39MxBvG01ls1FhGHAKUMzAqmrerD-n0vLbFX4X_4Xk37n7_Ba_ZIG805pZ1CbpxBb5imWCdL917juWIQw3JCtQr9NyaAqAeBMCSDaBBX3I8XCNWj-D7-tJxj9W5W0lrV-mbB1XaP2KYYZ2z9DgEN2k7Ks28VGLqWDq7ApnEGuvQyJn088a_BJRaCxXnZvMiIH6iBSVXCgm8HhFsA==" rel="nofollow" target="_blank" title="Blood Cancer Therapeutics: Global Markets to 2030">Blood Cancer Therapeutics: Global Markets to 2030</a> provides comprehensive market sizing, segmentation by therapy type and geography, competitive intelligence, and forecasts through 2030, offering a detailed analytical framework for stakeholders across the blood cancer therapeutics value chain. About BCC Research BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process. For media inquiries, email <a href="https://www.globenewswire.com/Tracker?data=fV_yPSaigcFV_LDah5yK2eB_9CFgWP0yBtEyjbTTbMfoAsv_uTw0VY9p9fIAdJlTY7AVO1fIKwhepNgJfPdtlB947oAT84soEYBP9nvd-ho=" rel="nofollow" target="_blank" title="press@bccresearch.com">press@bccresearch.com</a> or visit our <a href="https://www.globenewswire.com/Tracker?data=1GuJTTik0GeQEH2HBDDqlGNsuZVwzsYdy_dr7Jahf8Lde4NjvR39Mbhl8WAFFxgBKlv_o8fHg97E_fOt5de1h1kZ84qYx1aYd3D7nmBe1M9ASnKrp4i_b2cX_VgYI-ekekCFpMLwWBnvp_UYDIqSWsUaS3AzRuoTWXPT2sWFWZAi6SKo3c6lgGZzmX_GROEZ" rel="nofollow" target="_blank" title="media page">media page</a> for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying <a href="https://www.globenewswire.com/Tracker?data=ainQBQ8KiMUJNUJIAElhREOhec0q-HVn9uz-AU1g_drdcGqywG6p-8OJ5oqZmMmwVNo_2-WZaAJfRtnFDBzDcqYSRvYuBl1SB7Ohi6jp5x79dibmg2jM2Fv0W9J_FBOfXrgdsFceQChHB_he5uA4SlIomidj6guQSuNV9w7z0BGTflImYsA8fGSpQEnqaeJO" rel="nofollow" target="_blank" title="BCC Research LLC">BCC Research LLC</a> as the source and publisher. <pre>CONTACT: BCC Research LLC
50 Milk St., Ste. 16, Boston, MA 02109
press@bccresearch.com | +1 781-489-7301
www.bccresearch.com</pre> <img alt="" src='https://ml.globenewswire.com/media/ZjU5MTE2NzItM2E5Yy00NjA1LWExZmUtYjJmNDZmOGJmMjM1LTEwOTM4MjItMjAyNi0wOC0yNi1lbg==/tiny/BCC-Research-LLC.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Blood Cancer Therapeutics Market to Reach $125.5 Billion by 2030, Driven by Precision Medicine Advances and Expanding Immunotherapy Pipelines

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn